Recent research into retatruptide peptide highlight promising outlook for managing obesity and type diabetes. The molecule, a dual agonist of GLP-1 and glucose-dependent insulinotropic polypeptide, appears to present improved weight reduction and glycemic regulation versus existing treatments. On